Please use this identifier to cite or link to this item:
Title: Smoking cessation intervention in Australian general practice: a secondary analysis of a cluster randomised controlled trial.
Austin Authors: Gobarani, Rukshar K;Zwar, Nicholas A;Russell, Grant;Abramson, Michael J;Bonevski, Billie;Holland, Anne E ;Paul, Eldho;Cox, Narelle S ;Wilson, Sally;George, Johnson
Affiliation: Institute for Breathing and Sleep..
College of Medicine and Public Health, Flinders University, Bedford Park, South Australia..
Department of Infrastructure Engineering, Faculty of Engineering and Information Technology, University of Melbourne, Melbourne..
Department of Allergy, Immunology and Respiratory Medicine, Monash University, Melbourne..
School of Public Health and Preventive Medicine, Monash University, Melbourne..
Faculty of Health Sciences and Medicine, Bond University, Queensland, and School of Population Health, University of New South Wales, Sydney
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne..
Department of General Practice, and Southern Academic Primary Care Research Unit, Monash University..
Department of Physiotherapy, Alfred Health, Melbourne, Australia
Issue Date: 27-May-2021
Date: 2021
Publication information: The British journal of general practice 2021; 71(707): e458-e464
Abstract: GPs have limited capacity to routinely provide smoking cessation support. New strategies are needed to reach all smokers within this setting. To evaluate the effect of a pharmacist-coordinated interdisciplinary smoking cessation intervention delivered in Australian general practice. Secondary analysis of a cluster randomised controlled trial (RCT) conducted in 41 Australian general practices. In all, 690 current smokers were included in this study: 373 from intervention clinics (n = 21) and 317 from control clinics (n = 18). A total of 166 current smokers had spirometry-confirmed chronic obstructive pulmonary disease (COPD). In the intervention clinics, trained pharmacists provided smoking cessation support plus Quitline referral. Control clinics provided usual care plus Quitline referral. Those with COPD in the intervention group (n = 84) were referred for home medicines review (HMR) and home-based pulmonary rehabilitation (HomeBase), which included further smoking cessation support. Outcomes included carbon monoxide (CO)-validated smoking abstinence, self-reported use of smoking cessation aids, and differences between groups in readiness-to-quit score at 6 months. Intention-to-treat analysis showed similar CO-validated abstinence rates at 6 months in the intervention (4.0%) and control clinics (3.5%). No differences were observed in readiness-to-quit scores between groups at 6 months. CO-validated abstinence rates were similar in those who completed HMR and at least six sessions of HomeBase to those with COPD in usual care. A pharmacist-coordinated interdisciplinary smoking cessation intervention when integrated in a general practice setting had no advantages over usual care. Further research is needed to evaluate the effect of HMR and home-based pulmonary rehabilitation on smoking abstinence in smokers with COPD.
DOI: 10.3399/BJGP.2020.0906
ORCID: 0000-0003-2061-845X
Journal: The British journal of general practice : the journal of the Royal College of General Practitioners
PubMed URL: 33947668
PubMed URL:
Type: Journal Article
Subjects: general practice
smoking cessation
tobacco use
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on May 28, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.